Clinical Trials Logo

Clinical Trial Summary

The goal of this observation study is to test in relapsed or refractory acute lymphoblastic leukemia (R/R ALL) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is: • Effect of post-transplant blinatumomab treatment on immune reconstitution after transplantation. Participants will undergo immune repertoire sequencing(IR-SEQ) before blinatumomab treatment, 6 months and 1 year after transplantation. Researchers will compare patients who don't receive blinatumomab treatment after transplantation to see if TCR or BCR expression differs.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06075212
Study type Observational
Source Sichuan University
Contact
Status Not yet recruiting
Phase
Start date October 1, 2023
Completion date September 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT06111625 - Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL Phase 2
Not yet recruiting NCT06075238 - Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT Phase 2
Active, not recruiting NCT04849416 - A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) Phase 2
Completed NCT00339664 - Analyses of Human Samples Collected in Clinical Trials
Completed NCT01116193 - Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia Phase 2
Terminated NCT00569179 - A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies Phase 1